23 Apr 2013 07:00
Omega Diagnostics Group PLC
("Omega" or the "Company")
Grant of US Patent
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has been informed by the Burnet Institute that its exclusively licensed CD4 test for monitoring HIV-positive patients has been awarded a US Patent. The patent was granted on 2 April 2013 under number US 8,409,818 B2. The grant of this US patent widens the protection from territories where patents have already been granted in South Africa and the member states of the African Intellectual Property Organisation, and with patents pending in many other territories.
Commenting on the patent grant, Andrew Shepherd, CEO of Omega said: "We are delighted to learn of this US Patent award, extending the patent protection which already exists for our novel CD4 point-of-care test, and which is testimony to the years of hard work done by our colleagues at the Burnet Institute in partnership with others."
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) | |
Stephen Norcross/Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |